Patent ID: 9157121
Filing Date: 2015-10-13
Classification: A61K,A61P,C12Q

Abstract:
1. A method of administering iloperidone or a metabolite thereof to treating a human individual the method comprising: determining or having determined the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 ; and in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, administering to the individual a first quantity of iloperidone or a metabolite thereof, and in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is not associated with an increased risk of QT prolongation, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity, wherein a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, and the KCNQ1 genotype not associated with an increased risk of QT prolongation is non-CC at position 78927 of SEQ. ID. 1.